Targeting CDK7 Enhances the Antitumor Efficacy of Enzalutamide in Androgen Receptor–Positive Triple-Negative Breast Cancer by Inhibiting c-MYC–mediated Tumorigenesis
- 26 November 2024
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (6) , 870-883
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Among TNBC subtypes, the luminal androgen receptor (LAR) subtype expresses high levels of androgen receptor (AR) and generally responds poorly to neoadjuvant chemotherapy. AR has been reported as a promising therapeutic target for the LAR TNBC subtype. In this study, we evaluated the preclinical antitumor efficacy of enzalutamide, an AR inhibitor, in TNBC. Enzalutamide had moderate antiproliferative activity against AR-positive (AR+) TNBC cells (IC50 > 15 μmol/L). To enhance its antitumor efficacy, we performed high-throughput kinome RNAi screening and identified the cell cycle pathway as a potential target. Inhibition of cell cycle progression using the cyclin-dependent kinase 7 inhibitor KRLS-017 showed a synergistic antiproliferative effect with enzalutamide in AR+ LAR MDA-MB-453 and SUM185 TNBC cells. Downstream target analysis revealed that the enzalutamide and KRLS-017 combination dramatically reduced c-MYC expression at both mRNA and protein levels. c-MYC knockdown significantly suppressed growth of MDA-MB-453 and SUM185 cells to a degree comparable with that of enzalutamide and KRLS-017 combination treatment, whereas c-MYC overexpression reversed the synergistic effect. An enhancement in inhibition of tumor growth and suppression of c-MYC expression was further confirmed when enzalutamide was combined with KRLS-017 in an MDA-MB-453 mouse model. Our study suggests that KRLS-017 enhances the antitumor efficacy of enzalutamide by inhibiting c-MYC–mediated tumorigenesis and presents a potential new approach for treating AR+ LAR TNBC.Keywords
All Related Versions
Funding Information
- Breast Cancer Research Foundation (APR-18-006)
- Center for Cancer Research (CA016672-29, P30CA016672)
This publication has 60 references indexed in Scilit:
- CDK7 inhibition by THZ1 suppresses cancer stemness in both chemonaïve and chemoresistant urothelial carcinoma via the hedgehog signaling pathwayCancer Letters, 2021
- Phosphorylation of the androgen receptor at Ser81 is co‐sustained by CDK1 and CDK9 and leads to AR‐mediated transactivation in prostate cancerMolecular Oncology, 2021
- Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastomaCell Reports, 2021
- Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast CancerDiscover Oncology, 2018
- Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative DiseaseDiscover Oncology, 2015
- The Mediator complex in thyroid hormone receptor actionBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration‐resistant prostate cancerThe Prostate, 2013
- Expression of androgen receptors in triple negative breast carcinomasActa Histochemica, 2013
- The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancerMedical Oncology, 2011
- Mediator-Dependent Recruitment of TFIIH Modules in Preinitiation ComplexMolecular Cell, 2008